A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia

Nephrology Dialysis Transplantation

Volumn 31, Issue 4, 2016, Pages 646-655

  Kalra, Philip A ^a   Bhandari, Sunil ^b   Saxena, Sanjiv ^c   Agarwal, Dhananjai ^d   Wirtz, Georg ^e   Kletzmayr, Josef ^f   Thomsen, Lars L ^g   Coyne, Daniel W ^h  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c Pushpawati Singhaniya Research Institute   (India)

^d SMS MEDICAL COLLEGE   (India)

^e Dialysis Centre Kamen   (Germany)

^f DANUBE HOSPITAL   (Austria)

^g Pharmacosmos AS   (Denmark)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; iron isomaltoside 1000; iron treatment

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON ISOMALTOSIDE; TRANSFERRIN; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION; IRON ISOMALTOSIDE 1000;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GASTROENTERITIS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; TRANSFERRIN SATURATION CONCENTRATION; VERY ELDERLY; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEMODIALYSIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; DISACCHARIDES; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965179566     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv293     Document Type: Article

References (13)

1. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
2. Charytan C, QunibiW, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100: c55-c62
3. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
4. Wikstrom B, Bhandari S, Barany P et al. Iron isomaltoside 1000: A new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011; 24: 589-596
5. Hildebrandt PR, Bruun NE, Nielsen OWet al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. TATM 2010; 11: 131-137
6. Reinisch W, Staun M, Tandon RK et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108: 1877-1888
7. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100: 301-303
8. Coates A, Dillenbeck CF, McNeil DRet al. On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1983; 19: 1633-1637
9. Levey AS, Coresh J, Greene T et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772
10. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
11. QunibiWY, Martinez C, SmithMet al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607
12. Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: 1193-1198
13. Gupta DR, Larson DS, Thomsen LL et al. Pharmacokinetics of iron iromaltoside 1000 in patients with stage 5 chronic kidney disease on dialysis therapy. J Drug Metab Toxicol 2013; 4 doi: 10.4172/2157-7609.1000152